Indian biotech startups are increasingly targeting US and European markets for faster payments and higher profit margins. By securing international revenue early, these companies aim to overcome the slow adoption and pricing pressures often found within the domestic market.
Indian biotechnology startups are shifting their commercial strategy by prioritizing international markets to drive early revenue. While these companies continue to conduct research and development within India, they are increasingly looking to the US and Europe to achieve their first commercial milestones. This trend is driven by a need for more sustainable cash flow, which is currently harder to secure in the local market.
Why Global Markets Are Preferred
For many Indian biotech firms, the primary challenge in the domestic market involves long payment cycles and intense price sensitivity. Local buyers often extend payment terms up to six months and negotiate for thinner profit margins. In contrast, clients in the US and Europe, including established biotech firms and contract research organizations, typically offer payment terms of 30 to 45 days. These international partnerships often yield gross margins of 35% to 40% on specialized products such as recombinant proteins and specialty enzymes. This financial structure allows startups to generate annual recurring revenues between $500,000 and $2 million within their first two years, providing the capital necessary to fund further research and expand their teams.
Strategic Differences in Commercialization
While the industry is leaning toward a global-first revenue model, the approach remains varied among players. Some companies, such as Mestastop, have observed that Western markets exhibit a faster adoption rate for deep-tech innovations, whereas the Indian market often waits for international validation before fully embracing new therapies. However, other pioneers like Immuneel Therapeutics continue to prioritize an India-first approach. By focusing on domestic commercialization, such companies aim to demonstrate that advanced treatments, including CAR-T cell therapy, can be effectively developed and delivered to patients within the country.
Challenges in Clinical Development Funding
Despite the success in generating early revenue from abroad, the broader Indian biotech ecosystem faces a persistent funding gap, particularly during the validation and clinical trial stages. While early-stage research grants have seen improvement, later-stage clinical trials remain capital-intensive and difficult to fund. Experts note that government-backed initiatives, such as the ₹1 lakh crore Research, Development and Innovation Fund, are essential, but their impact depends on how effectively they are combined with institutional venture funding, shared R&D infrastructure, and access to cGMP-certified manufacturing facilities. For investors, the long-term viability of these startups will depend on their ability to balance global revenue generation with the capital-heavy requirements of proving their therapies in clinical settings.